MarketPeel
Insider Trading Intelligence
SL

Soleus Capital, Llc

LYRA
10% OWNER · LYRA THERAPEUTICS, INC. · CIK 0001786724
FILING MIX · LIFETIME58%/42%
BUYS
7
SELLS
5
TOTAL VALUE
$18.02M
COMPANIES
2
ACTIVE SINCE
May 2020
HOLDINGS NOW
527,070
AVG SELL PX
$16.00
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Soleus Capital, Llc, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%-2.40%+0.16%-2.56%-2.56%
14d2+50.00%-13.27%+2.02%-15.29%-15.29%
30d2+50.00%-3.90%+8.79%-12.70%-12.70%
60d2+50.00%-33.27%+9.58%-42.85%-42.85%
90d2+50.00%-17.84%+15.39%-33.23%-33.23%
180d2+50.00%-34.23%+16.35%-50.59%-50.59%
1y2+50.00%-49.31%+47.60%-96.91%-96.91%
2y2+50.00%-63.48%+48.85%-112.34%-112.34%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LYRA · 0 shares · as of May 5, 2020
0118,583237,165355,748474,330SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 7 buys / 5 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PBLS
PARABILIS MEDICINES, INC.
PURCHASE
527,070$9.48$5.00M527,070Jun 11, 2026Jun 29, 2026View →
PBLS
PARABILIS MEDICINES, INC.
PURCHASE
125,000$20.00$2.50M652,000Jun 11, 2026Jun 29, 2026View →
PBLS
PARABILIS MEDICINES, INC.
SALE
527,0700Jun 11, 2026Jun 29, 2026View →
PBLS
PARABILIS MEDICINES, INC.
PURCHASE
375,000$20.00$7.50M1,027,000Jun 11, 2026Jun 29, 2026View →
LYRA
LYRA THERAPEUTICS, INC.
SALE
16,909$16.00$270.5K457,421May 5, 2020May 15, 2020View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASE
104,608442,948May 5, 2020May 15, 2020View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASE
31,382$8.63$270.8K474,330May 5, 2020May 15, 2020View →
LYRA
LYRA THERAPEUTICS, INC.
SALE
31,3820May 5, 2020May 15, 2020View →
LYRA
LYRA THERAPEUTICS, INC.
SALE
3,607,2240May 5, 2020May 15, 2020View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASE
155,000$16.00$2.48M155,000May 5, 2020May 15, 2020View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASE
338,330338,330May 5, 2020May 15, 2020View →
LYRA
LYRA THERAPEUTICS, INC.
SALE
11,666,6660May 5, 2020May 15, 2020View →
Other insiders · LYRA
Loading peer insiders…
About this filer
CIK 0001786724
ROLE
10% Owner
PRIMARY
LYRA
COMPANIES
2
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001786724DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback